Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms (PREVENT) (QUE 15-280)
Status: Enrolling
Updated:  12/31/1969
Richard L. Roudebush VA Medical Center, Indianapolis, IN
mi
from
Indianapolis, IN
Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms (PREVENT) (QUE 15-280)
Status: Enrolling
Updated: 12/31/1969
Richard L. Roudebush VA Medical Center, Indianapolis, IN
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy
Pilot Study of the Use of Intravenous Immune Globulin in Hereditary Inclusion Body Myopathy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy
Pilot Study of the Use of Intravenous Immune Globulin in Hereditary Inclusion Body Myopathy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Idebenone to Treat Friedreich's Ataxia
A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Idebenone to Treat Friedreich's Ataxia
A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Status: Enrolling
Updated:  12/31/1969
SkyRidge Medical Center
mi
from
Lone Tree, CO
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Status: Enrolling
Updated: 12/31/1969
SkyRidge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Status: Enrolling
Updated:  12/31/1969
Beaver Dam Community Hospital
mi
from
Beaver Dam, WI
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
Status: Enrolling
Updated: 12/31/1969
Beaver Dam Community Hospital
mi
from
Beaver Dam, WI
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Click here to add this to my saved trials
Machines Assisting Recovery From Stroke
Machines Assisting Recovery From Stroke: Robotic Activity Mobility Center in a Fitness Center for People With Neurologic Disability
Status: Enrolling
Updated:  12/31/1969
Locomotor Control Lab
mi
from
Birmingham, AL
Machines Assisting Recovery From Stroke
Machines Assisting Recovery From Stroke: Robotic Activity Mobility Center in a Fitness Center for People With Neurologic Disability
Status: Enrolling
Updated: 12/31/1969
Locomotor Control Lab
mi
from
Birmingham, AL
Click here to add this to my saved trials
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Ghent,
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Ghent,
Click here to add this to my saved trials
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Loma Linda, CA
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
Click here to add this to my saved trials
Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers
A Behavioral and Functional Neuroimaging Study of Inhibitory Motor Control
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers
A Behavioral and Functional Neuroimaging Study of Inhibitory Motor Control
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
University of California
mi
from
San Diego, CA
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
University of California
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
Gillette Children's Specialty Healthcare
mi
from
Saint Paul, MN
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
Gillette Children's Specialty Healthcare
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated:  12/31/1969
South Metropolitan Health Service Fiona Stanley Hospital
mi
from
Murdoch,
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Status: Enrolling
Updated: 12/31/1969
South Metropolitan Health Service Fiona Stanley Hospital
mi
from
Murdoch,
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences (UAMS)
mi
from
Little Rock, AR
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences (UAMS)
mi
from
Little Rock, AR
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medicine New York-Presbyterian
mi
from
New York, NY
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medicine New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Ohio State University, James Cancer Center
mi
from
Columbus, OH
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Ohio State University, James Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
University Health Network
mi
from
Toronto,
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
University Health Network
mi
from
Toronto,
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials